Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 31Recruiting 15Active not recruiting 15Terminated 11Withdrawn 5Not yet recruiting 3Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 2Thoracic 1Sarcoma 1Lymphoid 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Melanoma 6Carcinoma, Renal Cell 6Squamous Cell Carcinoma of Head and Neck 5Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 3Neoplasms 2Lung Neoplasms 2Hodgkin Disease 2Head and Neck Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Transitional Cell 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Turcot syndrome 1Solid Tumors 1Skin Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Recurrence 1Rare Tumour 1Prostatic Neoplasms 1Post-Acute COVID-19 Syndrome 1Pancreatic Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Mouth Neoplasms 1Medulloblastoma 1Lung Diseases, Interstitial 1Liver Neoplasms 1Fibrolamellar hepatocellular carcinoma 1

Interventions

Bevacizumab 37Oxaliplatin 17Capecitabine 17Irinotecan 15Leucovorin 13HMPL-013 12Fluorouracil 12Cetuximab 11trifluridine tipiracil drug combination 7irinotecan sucrosofate 6tipiracil 5Trifluridine 5Specimen Handling 5Drug Therapy 5tislelizumab 4Standard of Care 4Mitomycin 4Magnetic Resonance Spectroscopy 4Injections 4Folfox protocol 4trametinib 3toripalimab 3pembrolizumab 3Nivolumab 3IFL protocol 3Colonoscopy 3Blood Specimen Collection 3Biopsy 3sotorasib 2sintilimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Colorectal Neoplasms × Nivolumab × Clear all
NCT07620574 2026-06-02

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Exelixis

Phase 3 Not yet recruiting
5,000 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT07576725 2026-05-08

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial

Fred Hutchinson Cancer Center

Phase 2 Not yet recruiting
50 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Clear-cell metastatic renal cell carcinoma, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Hodgkin Disease, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Kaposi, Colorectal Neoplasms, Carcinoma, Merkel Cell

NCT07403877 2026-02-11

TORCH-OPTIMA

Fudan University

Phase 2 Not yet recruiting
114 enrolled
Gastrointestinal

Turcot syndrome, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡